Apart from vaccination, this has to involve efficient vector control and proper case management
The advent of a new tetravalent vaccine against the dengue virus has thrown new light into the evidence-based management of dengue. An article recently published in the New England Journal of Medicine revealed that this vaccine confers about 80% protection to children vaccinated between 4 and 16 years of age without any major side effects. It was a double-blind, placebo-controlled, randomised, multi-centre trial which included 20,017 participants from the dengue-endemic countries. However, apart from promoting the use of the vaccine, gaining control over dengue will also require a holistic approach that has to include within its ambit vector control and proper case management.
Please click here to read more.